NasdaqGM - Delayed Quote USD

Cara Therapeutics, Inc. (CARA)

0.6716 -0.0355 (-5.02%)
At close: April 24 at 4:00 PM EDT
0.6800 +0.01 (+1.25%)
After hours: April 24 at 7:56 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
20,968.0000
20,968.0000
41,867.0000
23,028.0000
135,082.0000
Cost of Revenue
6,174.0000
6,174.0000
7,266.0000
--
--
Gross Profit
14,794.0000
14,794.0000
34,601.0000
23,028.0000
135,082.0000
Operating Expense
136,289.0000
136,289.0000
122,136.0000
112,111.0000
129,697.0000
Operating Income
-121,495.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
Net Non Operating Interest Income Expense
-604.0000
-604.0000
--
--
--
Other Income Expense
3,586.0000
3,586.0000
2,061.0000
642.0000
2,334.0000
Pretax Income
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
7,719.0000
Tax Provision
--
--
--
--
-691.0000
Net Income Common Stockholders
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Diluted NI Available to Com Stockholders
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Basic EPS
-2.15
-2.19
-1.59
-1.74
0.18
Diluted EPS
-2.15
-2.19
-1.59
-1.74
0.18
Basic Average Shares
53,969.6780
54,149.0590
53,653.5640
50,718.7650
47,413.2500
Diluted Average Shares
53,969.6780
54,149.0590
53,653.5640
50,718.7650
47,915.0300
Total Operating Income as Reported
-121,495.0000
-121,495.0000
-87,535.0000
-89,083.0000
5,385.0000
Total Expenses
142,463.0000
142,463.0000
129,402.0000
112,111.0000
129,697.0000
Net Income from Continuing & Discontinued Operation
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Normalized Income
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Interest Expense
604.0000
604.0000
--
--
--
Net Interest Income
-604.0000
-604.0000
--
--
--
EBIT
-117,909.0000
-117,909.0000
-85,474.0000
-88,441.0000
5,385.0000
EBITDA
-117,650.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
Reconciled Cost of Revenue
6,045.0000
6,045.0000
7,146.0000
--
--
Reconciled Depreciation
259.0000
259.0000
248.0000
248.0000
209.0000
Net Income from Continuing Operation Net Minority Interest
-118,513.0000
-118,513.0000
-85,474.0000
-88,441.0000
8,410.0000
Normalized EBITDA
-117,650.0000
-117,650.0000
-85,226.0000
-88,193.0000
5,594.0000
Tax Rate for Calcs
--
--
--
--
0.0003
12/31/2020 - 1/31/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ACET Adicet Bio, Inc.
1.8750
-10.71%
 
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
 
CLSD Clearside Biomedical, Inc.
1.3400
-2.19%
 
FGEN FibroGen, Inc.
0.9843
-8.01%
 
GTHX G1 Therapeutics, Inc.
3.9900
-4.77%
 
BCAB BioAtla, Inc.
2.3500
+4.91%
 
ACHL Achilles Therapeutics plc
0.7838
+0.10%
 
CABA Cabaletta Bio, Inc.
12.96
-2.70%
 
ALLK Allakos Inc.
1.0200
-2.86%
 
RAPT RAPT Therapeutics, Inc.
7.90
-1.25%